Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
GeneDx Holdings Corp. - Class A Common Stock
(NQ:
WGS
)
35.59
-0.17 (-0.48%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about GeneDx Holdings Corp. - Class A Common Stock
< Previous
1
2
Next >
GeneDx to Participate in Fall Investor Conferences
August 12, 2024
From
GeneDx
Via
Business Wire
GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 09, 2024
From
GeneDx
Via
Business Wire
GeneDx Announces Whole Genome Sequencing (WGS) Product Enhancements to Accelerate Diagnoses for More Patients
July 30, 2024
From
GeneDx
Via
Business Wire
GeneDx Reports Second Quarter 2024 Financial Results and Business Highlights
July 30, 2024
From
GeneDx
Via
Business Wire
GeneDx to Report Second Quarter 2024 Financial Results on Tuesday, July 30, 2024
July 11, 2024
From
GeneDx Holdings Corp.
Via
GlobeNewswire
GeneDx Announces Collaboration with Epic Aura to Expand Access to Rapid Whole Genome Sequencing (rWGS) Services to Inform Diagnosis in Affected Pediatric and Neonatal Patients
June 10, 2024
From
GeneDx Holdings Corp.
Via
GlobeNewswire
GeneDx Announces Patient Access Program to Expand Access to Exome Testing for Pediatric Epilepsy Patients
June 05, 2024
From
GeneDx Holdings Corp.
Via
GlobeNewswire
GeneDx to Participate in Upcoming Investor Conferences
May 22, 2024
From
GeneDx Holdings Corp.
Via
GlobeNewswire
GeneDx Reports First Quarter 2024 Financial Results and Business Highlights
April 29, 2024
From
GeneDx Holdings Corp.
Via
GlobeNewswire
GeneDx Announces Partnership with Komodo Health to Expand Access to World’s Largest Rare Disease Dataset
April 23, 2024
The Company will also participate in a World Orphan Drug Congress panel presentation highlighting the role of genomic sequencing in advancing precision medicine
From
GeneDx Holdings Corp.
Via
GlobeNewswire
GeneDx to Report First Quarter 2024 Financial Results on Monday, April 29, 2024
April 04, 2024
From
GeneDx Holdings Corp.
Via
GlobeNewswire
GeneDx to Present Data at the 2024 American College of Medical Genetics (ACMG) Annual Meeting Demonstrating Clinical Superiority of its Exome, Paving the Way for the Future of Genomics
March 14, 2024
From
GeneDx Holdings Corp.
Via
GlobeNewswire
GeneDx to Participate in 44th Annual Cowen Health Care Conference
February 26, 2024
From
GeneDx Holdings Corp.
Via
GlobeNewswire
GeneDx Reports Fourth Quarter and Full Year 2023 Financial Results and Issues Guidance for Full Year 2024
February 20, 2024
From
GeneDx Holdings Corp.
Via
GlobeNewswire
GeneDx to Report Fourth Quarter 2023 Financial Results on Tuesday, February 20, 2024
February 01, 2024
From
GeneDx Holdings Corp.
Via
GlobeNewswire
GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 24, 2024
From
GeneDx Holdings Corp.
Via
GlobeNewswire
GeneDx Announces Preliminary 2023 Financial Results
January 08, 2024
From
GeneDx Holdings Corp.
Via
GlobeNewswire
GeneDx Presents New Data at the American Epilepsy Society Annual Meeting Demonstrating That Exome Sequencing Outperforms Multi-Gene Panels for Patients with Epilepsy
December 01, 2023
New research from one of the largest exome sequencing studies of patients with epilepsy adds to the mounting evidence that exome sequencing offers superior clinical results compared to multi-gene...
From
GeneDx Holdings Corp.
Via
GlobeNewswire
GeneDx to Participate in 6th Annual Evercore ISI HealthCONx Conference
November 28, 2023
From
GeneDx Holdings Corp.
Via
GlobeNewswire
GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 20, 2023
From
GeneDx Holdings Corp.
Via
GlobeNewswire
GeneDx Reports Third Quarter 2023 Financial Results and Business Highlights
October 30, 2023
From
GeneDx Holdings Corp.
Via
GlobeNewswire
GeneDx to Report Third Quarter 2023 Financial Results on Monday, October 30, 2023
October 09, 2023
From
GeneDx Holdings Corp.
Via
GlobeNewswire
GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 22, 2023
From
GeneDx Holdings Corp.
Via
GlobeNewswire
GeneDx Announces Evolution of Executive Leadership Team
September 11, 2023
Melanie Duquette joining team as Chief Growth Officer to drive commercial excellence, Jennifer Brendel to take new role as Chief of Corporate Affairs amplifying the GeneDx brand and leadership...
From
GeneDx Holdings Corp.
Via
GlobeNewswire
GeneDx Announces Industry-Leading Accomplishment of 500,000 Clinical Exomes Sequenced
September 06, 2023
From
GeneDx Holdings Corp.
Via
GlobeNewswire
GeneDx Announces Data Demonstrating that Whole Exome and Genome Sequencing Report Fewer Variants of Uncertain Significance (VUS) than Multi-Gene Panel Testing Published in Genetics in Medicine
August 21, 2023
From
GeneDx Holdings Corp.
Via
GlobeNewswire
GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 08, 2023
From
GeneDx Holdings Corp.
Via
GlobeNewswire
GeneDx Reports Second Quarter 2023 Financial Results and Business Highlights
August 08, 2023
From
GeneDx Holdings Corp.
Via
GlobeNewswire
PacBio and GeneDx Launch Research Collaboration with the University of Washington to Study Long-Read Whole Genome Sequencing for Increased Diagnostic Yield in Neonatal Care
August 07, 2023
Study is first of its kind to compare diagnostic rates across short- and long-read sequencing platforms
From
GeneDx Holdings Corp.; PacBio
Via
GlobeNewswire
GeneDx and Prognos Health Announce Strategic Partnership to Help Rare Disease Patients More Rapidly Gain Access to Potential Treatment Options
July 19, 2023
Partnership allows commercial biopharma companies to leverage real-time data within comprehensive Prognos Marketplace to provide available treatment options for patients
From
GeneDx Holdings Corp.
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.